Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural correlates of foreign accent syndrome: Is white matter the key to the mystery?

Revue neurologique·2025
Same author

Surgical outcome of cerebral amyloid angiopathy-related cerebral hemorrhage-A multicenter comparative study.

Revue neurologique·2025
Same author

Neurological damage from recreational nitrous oxide use: Two distinct electroclinical profiles in a retrospective cohort.

Revue neurologique·2025
Same author

Prevalence and management of psychosis in an outpatient population with Parkinson's disease: A real-life descriptive study.

Revue neurologique·2025
Same author

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

ESMO open·2025
Same author

Parkinson's Disease, Speech and Neurosurgery.

Brain and behavior·2025

Related Experiment Video

Updated: Mar 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K

French consensus procedure for assessing cognitive function in Parkinson's disease.

K Dujardin1, N Auzou2, E Lhommée3

  • 1Université de Lille, Inserm U1171, Degenerative & Vascular Cognitive Disorders, 59000 Lille, France; CHU de Lille, Neurology and Movement Disorders, 59000 Lille, France.

Revue Neurologique
|June 20, 2016
PubMed
Summary
This summary is machine-generated.

A consensus procedure for assessing cognitive function in Parkinson's disease patients was developed. This standardized approach, recommended for research and clinical practice, ensures consistent neuropsychological evaluations across the French network.

Keywords:
AssessmentCognitionDementiaMild cognitive impairment

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.9K

Related Experiment Videos

Last Updated: Mar 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.9K

Area of Science:

  • Neurology
  • Neuropsychology
  • Movement Disorders

Background:

  • Parkinson's disease (PD) frequently involves cognitive impairment.
  • Standardized cognitive assessment in PD is crucial for research and clinical management.
  • The French expert centers for Parkinson's disease (NS-Park) network aimed to establish a consensus procedure.

Purpose of the Study:

  • To determine a consensus procedure for cognitive function assessment in Parkinson's disease patients.
  • To present the developed procedure and describe the selected neuropsychological tests.

Main Methods:

  • The Delphi method was employed by 13 experts for consensus building.
  • Criteria for test selection included French validation, minimal motor involvement, normative data, and international recognition.
  • Experimental tasks and tests requiring specialized equipment were excluded.

Main Results:

  • Two assessment levels were proposed: abbreviated and comprehensive.
  • For abbreviated assessment, the Montreal Cognitive Assessment (MoCA) was recommended for screening cognitive impairment or dementia.
  • For comprehensive assessment, evaluation of global efficiency and five key cognitive domains (attention/working memory, executive function, episodic memory, visuospatial function, language) using two tests per domain was advised.

Conclusions:

  • A unified cognitive assessment procedure is now established for the French Parkinson's disease network.
  • This procedure is recommended for both research and clinical practice.
  • The consensus procedure will enhance the standardization of neuropsychological assessments in Parkinson's disease.